Conchner: the 13-valent pneumococcal polysaccharide conjugate vaccine has obtained the drug registration certificate.

On the evening of June 20, Kexing announced that the company has obtained the Drug Registration Certificate for the 13-valent pneumococcal polysaccharide conjugate vaccine issued by the National Medical Products Administration. This vaccine is the first product in the company's pneumonia product portfolio to obtain a drug registration certificate, laying the foundation for the company's research and development of higher-priced pneumonia conjugate vaccines.